“Is Now the Time to Shake Up the pMDI Environment?” by Chris Baron, Director Business Development, Rx, EMEA at Aptar Pharma. This article explores how the use of propellants in pressurised metered dose inhalers has evolved – and how alternative propellants could be a catalyst for greater patient adherence. “Developing an In Vitro Dissolution and Release System for Orally Inhaled Drug Products” by Rob Price, Chief Scientific Officer, Nanopharm Ltd, an Aptar Pharma company.